Towards the development of a management protocol for Subjective Cognitive Decline: insights from a cross-sectional and longitudinal analyses of multimodal data from a memory clinic

Salvatore Mazzeo,Michael Lassi,Sonia Padiglioni,Valentina Moschini,Alberto Arturo Vergani,Maenia Scarpino,Giulia Giacomucci,Rachele Burali,Carmen Morinelli,Carlo Fabbiani,Giulia Galdo,Lorenzo Gaetano Amato,Silvia Bagnoli,Filippo Emiliani,Assunta Ingannato,Benedetta Nacmias,Sandro Sorbi,Antonello Grippo,Alberto Mazzoni,Valentina Bessi
DOI: https://doi.org/10.1101/2024.10.15.24315516
2024-11-01
Abstract:Introduction: Subjective cognitive decline (SCD) is considered as an early symptomatic stage of Alzheimer's disease (AD). This study aimed to develop a management protocol for SCD based on cross-sectional and longitudinal analyses. Methods: We enrolled 440 SCD patients who underwent neurological and neuropsychological assessments, MRI scans, APOE genotyping, and AD biomarker evaluations. Patients were followed for a median of 10 years. Results: A link was observed between SCD severity, insomnia, and benzodiazepine use. Aβ pathology was identified in 35% of cases. During follow-up, 87 patients progressed to mild cognitive impairment or dementia. The multi-modal clinical profile of each patient was processed by a machine learning model, predicting progression with 74% accuracy and providing a hierarchy of importance of features predicting progression. Discussion: Our findings support the development of a personalized clinical management protocol for SCD that considers demographic, clinical, cognitive and biological factors for both baseline characterization and prognostic purposes.
Neurology
What problem does this paper attempt to address?